p53-Therapeutics

p53-Therapeutics is a South Korean biotechnology company specializing in the development of precision oncology treatments that target the p53 tumor suppressor protein. Founded by experts in structural biology, the company focuses on discovering small molecules and peptides that can restore the wild-type function of mutant p53 proteins, which are found in a majority of human cancers. Their primary research efforts are directed toward the Y220C mutation, a common structural mutation in p53 that leads to protein instability and loss of function. By stabilizing these mutant proteins, p53-Therapeutics aims to reactivate natural apoptotic pathways in cancer cells. The company's pipeline is currently in the pre-clinical stage, targeting various solid tumors including ovarian and pancreatic cancers.